Wockhardt Share News - Latest Updates, Live News & More

Latest news about Wockhardt

Wockhardt Reports No Deviation in ₹1,000 Crore QIP Fund Utilization, Advances Towards NDA Filing for Novel Antibiotic Aug 08, 2025

Wockhardt completed two pre-NDA meetings with FDA for ZAYNICH®, targeting NDA filing in September. Q1 financials show revenue of ₹738 crore, EBITDA of ₹101 crore, and loss after tax of ₹108 crore. The company is exiting the US generic pharmaceutical segment, impacting ₹97 crore in goodwill. QIP fund utilization report shows ₹583.08 crore utilized out of ₹977.79 crore net proceeds. MIQNAF® launched in India, and 5 new patents filed and granted.

Wockhardt Reports Strong Standalone Q1 Results with 17% Revenue Growth, Takes ₹97 Crore Impairment on US Exit Aug 08, 2025

Wockhardt's Zaynich Proves Effective Against Severe Drug-Resistant Infection in U.S. Liver Transplant Patient Jul 28, 2025

Wockhardt Ltd Exits US Generics Market, Shifts Focus to Drug Discovery and Biologics Jul 15, 2025

Wockhardt Projects Profitability Growth, Targets 18-20% Margins Jul 14, 2025

More news about Wockhardt

14Jul 25

Wockhardt Ltd Exits US Generics Business, Focuses on Antibiotics and Biologics

Wockhardt Ltd has decided to exit its US generics business, filing for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for two wholly-owned US subsidiaries: Morton Grove Pharma and Wockhardt USA LLC. This strategic move aims to realign the company's focus towards new antibiotic drug discovery and biologics, particularly in insulin. The exit from the loss-making US generics business is expected to free up capital and management bandwidth for these innovative segments, potentially improving Wockhardt's long-term financial health and competitive position in specialized, high-value drug markets.

11Jul 25

Wockhardt Announces Major Strategic Shift: Exits US Generics to Focus on Innovation

Wockhardt Limited announces strategic realignment, exiting the US generic pharmaceutical segment to focus on new antibiotic drug discovery and biologicals portfolio in insulin. The company has filed for voluntary liquidation under Chapter 7 for its US subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. This move aims to address losses in the US generics business and redirect resources towards innovation-driven areas. The liquidation process is expected to complete within 15 months. Wockhardt remains committed to operations in India, UK, Ireland, and other profitable geographies.

01Jul 25

Wockhardt Unveils Zaynich Initiative for Global Licensing Agreements

Wockhardt, a prominent pharmaceutical company, has introduced the Zaynich Initiative, aimed at establishing worldwide licensing agreements. This strategic move is designed to expand Wockhardt's global footprint and potentially enhance its market presence. While specific details are limited, the initiative could lead to expanded market reach, revenue diversification, collaborative opportunities, and technology transfer. The pharmaceutical industry is closely watching the development of this initiative and its potential impact on Wockhardt's business strategy and market position.

06Jun 25

Wockhardt's Novel Antibiotic Zaynich Eyes $7 Billion Market Opportunity in US and Europe

Wockhardt Limited has announced that its novel antibiotic, Zaynich, has an addressable market opportunity of $7.00 billion in the United States and Europe. This potential revenue stream highlights the growing demand for innovative antibiotics in developed healthcare markets. The company's focus on this new drug demonstrates its strategic approach to addressing unmet medical needs and competing in high-value pharmaceutical segments. The success of Zaynich could have significant implications for both Wockhardt's growth and global public health efforts in combating antibiotic resistance.

29May 25

Wockhardt Narrows Q4 Loss, Reports 6% Revenue Growth

Wockhardt reported a consolidated net loss of ₹45.00 crore in Q4, significantly lower than the ₹177.00 crore loss in the same quarter last year. Revenue increased by 6% to ₹743.00 crore from ₹701.00 crore. The company's EBITDA turned positive at ₹64.00 crore, indicating improved operational performance. Akhilesh Krishna Gupta was reappointed as an Independent Director for a second five-year term.

08Apr 25

Wockhardt Expands European Presence with New Irish Subsidiary

Wockhardt Ltd's subsidiary, Wockhardt Bio AG, has incorporated a new wholly owned subsidiary in Ireland named Wockhardt Antibiotics (Ireland) Limited. The new entity, established on April 7, 2025, with an initial capital of 100 Euro, aims to strengthen Wockhardt's presence in the European market by channeling antibiotic products across the EU. This strategic move is expected to enhance the company's distribution network and leverage Ireland's favorable business environment as a gateway to Europe.

07Apr 25

Wockhardt to Exit US Generics Business Amid Market Challenges

Wockhardt, a major pharmaceutical company, has decided to exit its US generics business, marking a significant change in its operations. This move comes amid increasing competition and regulatory pressures in the US market. The decision suggests a reassessment of Wockhardt's global strategy and potential reallocation of resources to more profitable segments. The exit may create opportunities for other players in the US generics sector while raising questions about the challenges faced by international pharmaceutical companies in this market.